Neurocrine Biosciences, Inc. (NBIX) Revenue by Segment
Neurocrine Biosciences revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Neurocrine Biosciences's largest product or service was Product, with $954.30 million or 100% of revenue, up 39.9% from a year earlier. Next: Collaboration Revenue (under 1%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Neurocrine Biosciences, Inc.
NBIX
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Neurocrine Biosciences revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Product | $954.3M | $811.0M | $789.9M | $682.0M | 100% |
| Collaboration Revenue | $4.7M | $3.5M | $5.0M | $5.5M | under 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Neurocrine Biosciences?
Product: $954.30 million, or 100% of revenue, in Q2 fiscal 2026.
What are Neurocrine Biosciences's main products and services?
By revenue in Q2 fiscal 2026: Product (100%) and Collaboration Revenue (under 1%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
